To compare the risk of hospitalisation and associated costs in patients after treatment for prostate cancer.
Patients and Methods
We identified 29 571 patients aged 66-75 years without significant comorbidity from the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked database who were diagnosed with localised prostate cancer between 2004 and 2009 . We compared the rates of all-cause and treatmentrelated hospitalisation that occurred within 365 days of the initiation of definitive therapy. We used multivariable logistic regression analysis to identify determinants associated with hospitalisation.
Results
Men who underwent radical prostatectomy (RP) rather than radiotherapy (RT) had lower odds of being hospitalised for any cause after therapy [odds ratio (OR) 0.80, 95% confidence interval (CI): 0.74-0.87]. Patients who underwent RP rather than RT had higher odds of being hospitalised for treatment-related complications (OR 1.15, 95% CI: 1.03-1.29). However, men who underwent external beam RT (EBRT)/ intensity modulated RT (IMRT) (OR 0.84, 95% CI: 0.72-0.99) had a 16% lower odds of hospitalisation from treatmentrelated complications than patients undergoing RP. Using propensity score-weighted analyses there was no significant difference in the odds of hospitalisation from treatmentrelated complications for men who underwent RP vs RT (OR 1.06, 95% CI: 0.92-1.21). Patients hospitalised for treatmentrelated complications after RT were costlier than patients who underwent RP (Mean $18 381 vs $13 203, P < 0.001).
Introduction
Prostate cancer remains the most commonly diagnosed solid organ tumour among men in the USA, with an estimated 220 800 new cases and 27 540 deaths in 2015 [1] . Broadly speaking, curative treatment options for prostate cancer include surgery and radiotherapy (RT) [2, 3] . Driven by intensive PSA screening over the last quarter of a century, prostate cancer has witnessed a marked stage migration [4] , toward a more indolent course in most newly diagnosed cases [5] .
In recent years, there has been a concerted effort to maximise the value of healthcare delivery by improving the quality of medical outcomes and by reducing unnecessary costs [6] . Prostate cancer represents a high-yield target for value-based reform given the preponderance overtreatment, as well as the expensive technologies required for RT and surgery. Currently, the Centers for Medicare and Medicaid Services (CMS) has initiated a hospital readmission reduction programme in accordance with the Affordable Care Act to reduce payments to hospitals with excessive readmissions for the following procedures and diagnoses: acute myocardial infarction, congestive heart failure, pneumonia, chronic obstructive pulmonary disease, and elective total hip arthroplasty and total knee arthroplasty [7] . Similar payment reductions may ensue for readmissions after treatment for common malignancies, including prostate cancer. Prior studies have rigorously assessed complications, interventions to treat complications, as well as the time interval to first complication among patients who underwent surgery or RT [8] [9] [10] . While studies often report 30-and 90-day readmission rates, CMS uses readmission 30-days following intervention when discerning payment reductions [7] . However, the use of relatively short readmission time intervals may inaccurately assess delayed hospitalisation rates after prostate cancer treatment [8] . In this context, the rate of hospitalisation after prostate cancer treatment and the associated costs in the general population is currently unknown. The objective of the present study was to assess the risk, predictors, and costs of hospitalisation after primary treatment for prostate cancer.
Patients and Methods

Data Sources
We used Surveillance, Epidemiology, and End Results (SEER)-Medicare data for analysis, which are composed of a linkage of population-based cancer registry data from 16 SEER areas with Medicare administrative data. The SEER programme covers~26% of the USA population, and the Medicare programme provides benefits to 97% of Americans aged ≥65 years [11] .
Study Population
Due to baseline differences between patient populations undergoing RT and surgery, we limited our analysis to only include patients expected to be candidates for either radical prostatectomy (RP) or RT based on age and limited comorbid medical conditions. From the SEER-Medicare linked database, we identified 29 571 patients who met the following criteria: age 65-75 years, Charlson Comorbidity Index (CCI) scores of 0 or 1, localised prostate cancer (clinical stage T1/T2), diagnosed with prostate cancer between 2004 and 2009, and treated with RP or RT. To ensure data completeness and to allow enough follow-up time to evaluate treatment and hospitalisation, we included only patients who had full medical insurance coverage provided by Medicare Part A and Part B during the 12 months before and after treatment and who were not Health Maintenance Organisation members. Patients who received both RP and RT were excluded from analysis (192 patients). Patients with a diagnosis of any other cancer before or after prostate cancer diagnosis were excluded (Fig. 1) .
Study Variables
Patient demographics and tumour characteristics at the time of diagnosis were extracted from the SEER-Medicare Patient Entitlement and Diagnosis Summary File (PEDSF). Patient treatment information was extracted from Medicare claims files for durable medical equipment (DME), physician (NCH), inpatient service (MEDPAR), and outpatient service files (OUTPAT).
The primary exposure was the treatment received within 6 months after diagnosis, identified using International Classification of Diseases 9th edition (ICD-9) procedure codes and Current Procedural Terminology (CPT) codes in Table S1 . The primary outcome of interest was the rate of hospitalisations within 12 months following initiation of treatment. Hospitalisation for the index RP was not considered as part of the outcome.
For descriptive purposes, patients were classified into two, mutually exclusive categories based on the treatment received within this initial period: RP (open, minimally invasive or perineal) and RT (external beam, brachytherapy or both) with or without androgen-deprivation therapy (ADT, luteinising hormone-releasing hormone agonist or orchidectomy) (Table S1 ). CPT-4 code 55899 (unspecified male genitourinary procedure) may sometimes be used with an open RP administrative code to specify minimally invasive RP with robotic assistance for private health plans, but Medicare does not recognise this coding schema, and very few men had this combination of codes; therefore, this was not used to identify minimally invasive RP.
We obtained the age, race, geographic region, census variables (urban/rural, education, poverty level), diagnosis year, and stage (T1/T2) from the PEDSF file. Treatment variables including RP, RT, and ADT use were determined from Medicare claims. Comorbidity was assessed using the Klabunde modification of the CCI during the year before diagnosis [12] . The Klabunde modification uses comorbid conditions identified by the CCI and incorporates the diagnostic and procedure data contained in Medicare physician (Part B) claims. Variables were categorised as in Table 1 .
Statistical Analysis
We evaluated the rate of hospitalisation for any cause as well as hospitalisation for treatment-related complications that occurred within 12 months of treatment initiation. Prior adjusted analyses where sensitivity analyses performed excluded patients with pre-existing conditions have demonstrated similar results. Based on prior studies [13] , we derived our definition for recording hospitalisation for treatment-related complication vs any cause. Conditions listed in the Table S2 that were not present in the Medicare claims during the 12 months preceding treatment were deemed treatment-related complications. We calculated and compared the hospitalisation rates from a treatment-related complication for patients who underwent RT and RP. The most common reasons for hospitalisation from a treatmentrelated complication (categorised as urinary, gastrointestinal, etc.) were identified. Total cost of hospitalisation for all-cause and treatment-related hospitalisations were calculated as the sum of the Medicare reimbursement, the amount that was made by a primary payer other than Medicare, the total of all claims passed through for the stay, and patients' deductible and Part A co-insurance.
The rates of hospitalisation and 95% CIs were calculated and compared between the two treatment groups. We used 
Results
Of the 29 571 patients who were included in the analysis, 21 301 patients received RT and 8 270 patients underwent RP within 6 months of cancer diagnosis. ADT was used in over a third of patients who underwent RT (7 892, 37.1%).
The demographics of our study population are summarised in Table 1 . The 1 510 patients excluded from analyses of the hospitalisation with treatment-related complications were because they had pre-existing conditions.
Patients were more frequently hospitalised for any condition within 365 days following RT than RP (15.9% vs 12.7%, P < 0.001). However, there was no significant difference in hospitalisation from treatment-related complications between the treatment groups (6.3% vs 6.5%, P = 0.523) ( Table 2 ). Table 4) . Using propensity score-weighted analyses, there was no statistically significant difference in the incidence of hospitalisation from treatment-related complications for men who underwent RP vs RT (OR 1.04, 95% CI: 0.91-1.19). Compared with RP, the incidence of treatment-related complications were not significantly different for brachytherapy (OR 0.94, 95% CI: 0.80-1.11) and combined EBRT/brachytherapy (OR 0.91, 95% CI: 0.77-1.07). However, patients who underwent EBRT/IMRT (OR 0.84, 95% CI: 0.72-0.99) had a 16% lower odds of hospitalisation from treatment-related complications than patients undergoing RP.
For costs, we found that patients who underwent RT had greater healthcare expenditures for any cause hospitalisation when compared with patients undergoing RP (mean $16 465 vs $13 597, P < 0.001). Similarly, patients hospitalised for treatment-related complications after RT were costlier than RP patients (mean $18 381 vs $13 205, P < 0.001) ( Table 5 ).
Discussion
Treatment options for clinically significant prostate cancer may include RP, EBRT, and brachytherapy with active surveillance reserved for men diagnosed with indolent disease [2, 3] . Prior research has shown varying complication rates and need for additional procedures after each treatment method [9] . In recent years, there has been a concerted effort to maximise the value of healthcare delivery by improving the quality of medical outcomes through decreased readmissions and reducing unnecessary costs [7] . In the present study, of the 29 571 patients undergoing RP or RT as their primary treatment for prostate cancer, with the exception of EBRT/ IMRT, there was no statistically significant difference in the odds of hospitalisation from treatment-related complications. Moreover, costs from hospitalisation after treatment were *Hospitalisation defined as readmission within 365 days of initial treatment; **P from t-test for overall difference among treatments.
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© 2016 The Authors BJU International © 2016 BJU International significantly higher for men undergoing RT than RP. We provide one of the first population-based analyses to further discern determinants costs of hospitalisation after primary treatment for prostate cancer.
Our present study has several important findings. First, in a cohort of men who would theoretically be candidates for either RP or RT because of age and good overall health, we found men who underwent RT more likely to be hospitalised for any reason. Prior studies have shown that men with advanced age and increased comorbidities were more likely to have complications after treatment for prostate cancer [14] . This is attributed to the variation in patient demographics undergoing RT compared with RP, those undergoing RT are often more unwell and more likely to have other competing risks for hospitalisation [14] [15] [16] . Our present results are relevant given the fact that we limited our cohort to those without significant comorbidities or advanced age. In addition, we were able to show that men without significant comorbidities and more recent year of RP were less likely to be hospitalised, which is consistent with prior reports [14] . Furthermore, tumour biology was a significant determinant of risk of overall and treatment-related hospitalisation. While we cannot conclude a cause and effect, there was an association between tumour biology and hospitalisation risk. Taking these patient factors into account and as suggested by current guidelines, physicians should incorporate life expectancy and competing risks when counselling patients on appropriate treatments.
Second, we found geographic variability in hospitalisation after primary treatment for prostate cancer. Specifically, men treated in rural areas and in the West were more likely to be hospitalised after primary treatment. While significantly different, the absolute differences observed were small and the comparative rates of hospitalisation were close. Our geographic variability observed is consistent with other prior reports about costs of treatment where regional differences are not due to differences in the prices of medical services, levels of illness or the socio-demographic characteristics of a region, but rather secondary to a greater quantity of medical services delivered including greater propensity for readmission after treatments in high cost areas [17] . Quality of care may not necessarily be better in regions of higher utilisation, and may in fact be significantly worse than quality of care in areas that use fewer resources [18] . The culture in medical communities is an important determinant of the quantity of medical care delivered [18] , and may be the ratelimiting step when attempting to attenuate regional variation in hospitalisation after treatment for prostate cancer.
Third, in multivariable analyses we found that men treated with RP were more likely to be hospitalised due to a treatment-related complication than men treated with RT. Our present findings are consistent with prior reports suggesting complications related to therapy following RP occur sooner than that of RT patients [19] . However, while we identified a statistically significant difference in likelihood of hospitalisation after treatment, the absolute difference was very small and may not be clinically relevant. Moreover, we attempted to provide a comparable group of men to discern potential differences in risk of treatment-related complications requiring hospitalisation. There may be other confounding variables that we are unable to control and further determinants needed to be discerned about hospitalisation risk. In the present study, propensity score-weighted analyses identified no significant difference in treatment-related hospitalisation except that patients who underwent EBRT/ IMRT had 16% lower odds of treatment-related hospitalisation than patients undergoing RP. These findings support prior studies confirming a decreased side-effect profile associated with three-dimensional conformal RT and IMRT [20] . To our knowledge, this is the first comparative effectiveness study to discern risk of hospitalisation after primary treatment with RP or RT for prostate cancer. Other studies have critically assessed complications and additional procedures following either surgery or RT [9, 10] . However, because patients treated with RT were older and more comorbid, selection bias limits the strength of conclusions that can be drawn from those studies.
Lastly, RT patients had higher attributable costs overall and related to complications when hospitalised when compared with RP patients. Recently, Wallis et al. [9] examined rates of interventions to manage complications after RT or RP using SEER-Medicare data within the same time period as the present study. While they did not evaluate associated costs, RT patients had significantly higher rates of urological procedures and anal-rectal procedures after RT. Our present analysis included diagnosis and procedure codes that further support the likelihood of increased complications requiring intervention, hospitalisations, and the associated increased costs after RT. These increased costs associated with RT should be balanced with individual risks of complicationrelated hospitalisation associated with certain types of RT such as EBRT/IMRT. These findings are important in the current healthcare climate, with an ever increasing demand for comparative effectiveness research discerning high quality cost-effective care over the entire care cycle [6] . In the hospital readmission reduction programme, the CMS currently uses 30-day readmission rates as a benchmark [7] . With payment penalties for increased readmissions in the setting of bundled payments and increased pressures to improve the value of care across the entire care cycle, there will be an increased need for comparative effectiveness research [21, 22] . Critical assessment of hospitalisation risks for disease and treatments that may occur at greater than 30 or even 90 days are imperative to understanding how best to allocate resources appropriately.
While our present findings are policy relevant, they must be interpreted in the context of the study design. First, SEERMedicare is limited to men aged ≥65 years and our results may not be generalisable to younger men diagnosed with prostate cancer. Second, neither SEER nor Medicare explicitly identifies those men who are being treated with robot-assisted RP. However, patients who undergo minimally invasive RP are more likely to have undergone robot-assisted surgery, which was increasing during the study period [23] . Third, we excluded PSA values in the present study due to preliminary evaluation of SEER data uncovered problems with the quality and interpretation of the PSA value [24] . While this questions the validity of large datasets, prior studies have suggested the limited impact PSA may have on disease risk stratification with patients having similar tumour characteristics as those with complete data [25] . Fourth, claims data are primarily designed to provide billing information and may not accurately capture all clinical information [13] . However, prior studies have shown a high degree of correlation between use of Medicare claims to detect complications after RP [26] . Fifth, our present results may not reflect long-term risk of hospitalisation after either treatment. Side-effects after RT treatment may take many years to become clinically apparent. However, recent long-term outcomes research have shown similar incidence of certain treatment-related complications [27] . Lastly, while we attempted to control for known predictors for hospitalisation, the findings are hypothesisgenerating and there may be omitted variable bias. While we used the CCI, there may have been differences in health between the RP and RT groups that were not reflected in the CCI scores. However, observational studies reflect practice patterns and when compared with results from wellconducted randomised controlled trials they do not appear to overestimate treatment effects nor differ qualitatively [28, 29] .
Conclusions
With the exception of men who underwent EBRT/IMRT, there was no statistically significant difference in the odds of hospitalisations from treatment-related complications. Costs from hospitalisations after treatment were significantly higher for men undergoing RT compared with RP. Our present findings are relevant in the context of penalties linked to hospital readmissions and bundled payment models.
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